When she was eight years old, Laura Deming realized that we were all going to die of a condition called aging. Ever since, her driving passion has been to slow aging and eliminate age-related disease. She started working in Cynthia Kenyon's lab when she was 12 to work on aging in worms, and matriculated at MIT when she was 14. At 17, she was one of the youngest 20under20 fellows awarded $100,000 by Peter Thiel to dropout to found the first longevity-focused venture capital fund, Longevity Fund (5 IPOs across 3 funds with $37 AUM, over a billion in follow-on funding raised, and top-decile DPI). Now, Laura is the cofounder and a Venture Partner at age1, named after her 3rd fund that produced companies such as Loyal, Fauna Bio, Gordian Biotechnology, Rubedo Life Sciences, etc. age1 is a new $50M fund with cofounder Alex Colville devoted to catalyzing early-stage longevity biotechs and venture incubation.